Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Political Science Scholar with Personal
September 10, 2007
- NEW PRODUCTS／Daiichi Sankyo: Fentanyl for Infants
September 10, 2007
- RIKEN Kobe Institute to Develop
September 10, 2007
- Takeshi Erikawa Appointed
September 10, 2007
- Korosho to Train Senior CRCs, Data Managers, IRB Members
September 10, 2007
- Korosho to Demand \22,160.4 Bil., Up 3.2%, in FY2008
September 10, 2007
- Korosho to Standardize Forms for Clinical Trial Documents
September 10, 2007
- Japan's 1st Drug for ADHD Recommended for Approval
September 10, 2007
- R&D NEWS IN BRIEF
September 10, 2007
- Korosho to Create "Healthcare Clusters" to Promote Drug Discovery
September 10, 2007
- Our Generics Had Economic Effects of \58.6 Bil. in 2006: Taiyo Yakuhin
September 10, 2007
- JMA Proposes Same Prices for Original Drugs and Generics
September 10, 2007
- Major Pharmas Tie Up with Generic Firms: Seminar
September 10, 2007
- REGULATORY NEWS IN BRIEF
September 10, 2007
- JGPRG to Designate Oct. as "Generic Drug Promotion Month"
September 10, 2007
- NBI to Go on Offensive in the Market for ARBs with 1,000 MRs
September 10, 2007
- GENERICS NEWS IN BRIEF
September 10, 2007
- Leiden Bio Science Park Is Ideal Gateway to Europe: F. van As of Leiden City
September 10, 2007
- Reimbursement Begins for 4 Lab Tests
September 10, 2007
- Korosho Asks Makers to Present Criteria for Allowances ASAP after Notification of New NHI Prices
September 10, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…